1. Home /
  2. Biotechnology

Biotechnology

Behind the Cutting Edge Technology: The History of Amgen

Behind the Cutting Edge Technology: The History of Amgen

This biotechnology company got it's start California. Watch 'Behind the Label' TheStreet's new video series to learn more.

I Like These 2 Smaller Name Biotech Stocks

I Like These 2 Smaller Name Biotech Stocks

I still believe it will be a big year for buyouts across the biotech industry.

Moderna's Small Base Could Surprise on the Upside

Moderna's Small Base Could Surprise on the Upside

Prices have moved above the early January high giving us the simple definition of an uptrend.

Incyte Expected to Earn 17 Cents a Share

Incyte Expected to Earn 17 Cents a Share

Incyte revenue expected to rise 9.5% to $486.2 million.

Gilead Sciences Falls on Failed Cirrhosis Drug Trial of Selonsertib

Gilead Sciences Falls on Failed Cirrhosis Drug Trial of Selonsertib

Gilead Sciences says Selonsertib, a new drug for treating NASH, a type of liver disease, failed Phase 3 trials.

It's a Stock Picker's Delight Right Now

It's a Stock Picker's Delight Right Now

With cash levels high, those players who are not well-positioned for upside action are scrambling to put money to work and are helping to propel prices higher.

FDA Cracks Down On Misleading Dietary Supplements

FDA Cracks Down On Misleading Dietary Supplements

The agency delivers 17 different warnings to companies advertising that their supplements help treat Alzheimer's, diabetes and cancer.

Gilead Sciences Drops Following Earnings Miss

Gilead Sciences Drops Following Earnings Miss

The biotech company reports downside bottom-line results, though it beats on revenue.

Array BioPharma Surges as Loss Is Narrower Than Expected

Array BioPharma Surges as Loss Is Narrower Than Expected

The cancer drugmaker post narrower-than-expected losses for the quarter and strong revenue growth.

Merck Is Named No. 1 Pharma Pick at Bank of America

Merck Is Named No. 1 Pharma Pick at Bank of America

Strong sales of key cancer treatment drug Keytruda are expected to continue to drive revenues and earnings.